Skip to main content
. 2011 Dec;85(24):12910–12918. doi: 10.1128/JVI.06268-11

Fig. 7.

Fig. 7.

Treatment of infected cell extracts. (A) Cell extracts from gK-V5-TEV-infected cells were immunoprecipitated with anti-V5 antibody and mock or TEV treated for 1 h at 30°C. Immunoprecipitates were tested for the presence of gK using anti-V5 antibody. Lane 1 (PBS), cell extracts mock digested in PBS buffer; lane 2 (PBS + E), cell extracts digested with AcTEV in PBS; lane 3 [PBS + INACT.E (CP)], PBS plus inactivated enzyme passed through a desalting column; lane 4 [PBS + E (CP)], PBS plus enzyme passed through a desalting column. (B) Densitometric analysis of immunoblots shown in panel A.

HHS Vulnerability Disclosure